The Pacific Ovarian Cancer Research Consortium (POCRC) is a community-based, multidisciplinary, translational research program that involves clinicians, laboratory scientists and public health scientists from several research and medical institutions along the Pacific Coast. The broad based approach takes full advantage of the scientific expertise available locally and allows the pooling of clinical resources, thus facilitating population-based studies despite the low incidence of ovarian cancer. The themes of the program are 1) risk modeling and early detection of disease, 2) prevention of disease progression using immunotherapeutic strategies, and 3) prognostic classification and development of novel treatments for advanced disease based on identification of genetic alterations that predict disease behavior. Our hypothesis is that through early detection we can improve outcomes significantly, because 1) currently available treatments are more effective in disease confined to the ovary, and 2) we will develop novel, relatively non-toxic treatments that will be particularly effective in early-stage disease. The tools of molecular biology, immunology and immunotherapy are emphasized in the translational research program. The POCRC will conduct four research projects that will be supported by four cores: a Leadership Core, a Clinical Core, a Specimen Core, and an Informatics Core. Each of the four projects in our Renewal Application relates to at least one of the translational areas outlined in the SPORE guidelines and together the program encompasses all five. Early detection, a key to improved outcomes for women with ovarian cancer and a major focus of our SPORE, is the focus of our first project. Risk modeling, which is needed for implementation of both early detection and prevention programs, is the focus of our second project. Therapy to improve the outcomes for women with advanced disease is the focus of our third project, which explores the potential for eliminating tumor using adoptive T-cell therapy. Identification of molecular targets for therapy and prognostic classification of disease are the goals of our fourth project, which includes functional characterization of potentially relevant genes. All of these projects build on work performed during the current funding period. A Developmental Research Program and a Career Development Program are also included as part of our Renewal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA083636-06
Application #
6712002
Study Section
Special Emphasis Panel (ZCA1-GRB-G (O1))
Program Officer
Arnold, Julia T
Project Start
1999-09-30
Project End
2009-06-30
Budget Start
2004-09-30
Budget End
2005-06-30
Support Year
6
Fiscal Year
2004
Total Cost
$1,733,829
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998

Showing the most recent 10 out of 187 publications